Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 04, 2020

SELL
$1.75 - $6.2 $594,368 - $2.11 Million
-339,639 Closed
0 $0
Q2 2020

Aug 06, 2020

SELL
$0.91 - $2.36 $13,765 - $35,699
-15,127 Reduced 4.26%
339,639 $618,000
Q1 2020

May 06, 2020

SELL
$1.01 - $3.42 $2.61 Million - $8.85 Million
-2,589,023 Reduced 87.95%
354,766 $358,000
Q4 2019

Feb 07, 2020

BUY
$0.87 - $2.89 $1.9 Million - $6.3 Million
2,178,665 Added 284.75%
2,943,789 $8.18 Million
Q3 2019

Nov 08, 2019

BUY
$1.34 - $2.4 $183,747 - $329,100
137,125 Added 21.84%
765,124 $1.17 Million
Q2 2019

Aug 06, 2019

BUY
$1.46 - $4.44 $916,878 - $2.79 Million
627,999 New
627,999 $0
Q4 2018

Feb 06, 2019

SELL
$3.5 - $9.66 $943,946 - $2.61 Million
-269,699 Closed
0 $0
Q3 2018

Nov 08, 2018

BUY
$7.85 - $12.35 $2.12 Million - $3.33 Million
269,699 New
269,699 $2.55 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.